Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Carcinoid tumors.

Russell G Robertson1, William J Geiger, Nancy B Davis

  • 1Department of Family Medicine, Feinburg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA. rrdoc@northwestern.edu

American Family Physician
|August 18, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study.

Urologic oncology·2025
Same author

Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.

The oncologist·2025
Same author

Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study.

Cancer medicine·2025
Same author

Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.

European urology·2025
Same author

Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.

European urology oncology·2024
Same author

Editorial: Bladder preservation options for bladder cancer.

Frontiers in oncology·2024
Same journal

For Post-stent Patients With Atherosclerotic Coronary Vascular Disease Who Are Taking an Anticoagulant, Adding Aspirin Worsens Outcomes.

American family physician·2026
Same journal

Nausea and Vomiting During Pregnancy.

American family physician·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management.

American family physician·2026
Same journal

Aerobic Exercise Is the Better Exercise Modality for Knee Osteoarthritis.

American family physician·2026
Same journal

Overscreening Leads to Overdiagnosis of MASLD.

American family physician·2026
Same journal

Type 2 Diabetes: Outpatient Insulin Management.

American family physician·2026
See all related articles

Carcinoid tumors, a type of neuroendocrine neoplasm, are increasingly recognized as malignant despite their slow growth. Diagnosis and prognosis depend heavily on tumor location and metastatic spread.

Area of Science:

  • Oncology
  • Gastroenterology
  • Pathology

Background:

  • Carcinoid tumors are rare, slow-growing neuroendocrine neoplasms.
  • Historically considered benign, they are now recognized as increasingly malignant.
  • Clinical presentation is often delayed until metastatic spread or carcinoid syndrome occurs.

Purpose of the Study:

  • To review the incidence, origin, and clinical characteristics of carcinoid tumors.
  • To highlight the increasing incidence and malignancy of these neoplasms.
  • To emphasize the diagnostic and prognostic factors influencing patient outcomes.

Main Methods:

  • Literature review of carcinoid tumor characteristics.
  • Analysis of tumor origin based on embryonic gut divisions.

Related Experiment Videos

  • Discussion of diagnostic challenges and treatment implications.

    • Main Results:

    • Carcinoid tumors originate from foregut, midgut, or hindgut structures, influencing location (lungs, stomach, small intestine, colon, rectum).
    • Midgut carcinoid tumors are most frequently associated with carcinoid syndrome.
    • Diagnosis is often incidental, discovered during surgery for other conditions.

    Conclusions:

    • Carcinoid tumors demonstrate increasing incidence and malignancy.
    • Tumor location and extent of metastasis are critical for treatment and prognosis.
    • Early detection and understanding of neuroendocrine neoplasm behavior are crucial.